Get started
Author

Thomas J. F. Blankenstein

Observed names: Blankenstein, T., Blankenstein, Thomas, T BLANKENSTEIN, T Blankenstein, T. BLANKENSTEIN, T. Blankenstein, T. J. F. Blankenstein, Thomas Blankenstein, Thomas JF Blankenstein
Observed institutions: National Institutes of Health, St. Jude Children's Research Hospital, Vita-Salute San Raffaele University, University of Cologne, Chinese Academy of Sciences, Max Delbrück Center, Chapel Allerton Hospital, University Hospital Augsburg, Helmholtz Munich, LMU Klinikum, Medizinische Hochschule Hannover, Humboldt-Universität zu Berlin, Institute of Biophysics, Ludwig Cancer Research, München Klinik, Institute of Immunology, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Deutsches Konsortium für Translationale Krebsforschung, Stiftung Charité, Institut für Immunologie, The University of Tokyo, Freie Universität Berlin, Charité - Universitätsmedizin Berlin, Ludwig-Maximilians-Universität München, Kumamoto University
ORCID: 0000-0002-3357-4321
Observed ORCID: 0000-0002-3357-4321
OpenAlex ID: A5034157963
CCR7 Governs Skin Dendritic Cell Migration under Inflammatory and Steady-State Conditions
2004 · Lars Ohl, Mariette Mohaupt, et al. · Immunity · 1,084
PDF
From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression
2003 · Oleg Schmidt-Kittler, Thomas Ragg, et al. · Proceedings of the National Academy of Sciences · 631
CD4 + T Cell–Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFNγ Receptor Expression by Nonhematopoietic Cells
2000 · Zhihai Qin, Thomas Blankenstein · Immunity · 511
PDF
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer
2002 · Christoph A Klein, Thomas JF Blankenstein, et al. · The Lancet · 479
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
2005 · Gerald Willimsky, Thomas Blankenstein · Nature · 445
The determinants of tumour immunogenicity
2012 · Thomas Blankenstein, Pierre G. Coulie, et al. · Nature reviews. Cancer · 441
B cells inhibit induction of T cell-dependent tumor immunity
1998 · Zhihai Qin, Günther Richter, et al. · Nature Medicine · 419
CD4-Positive T Lymphocytes Provide a Neuroimmunological Link in the Control of Adult Hippocampal Neurogenesis
2009 · Susanne A Wolf, Barbara Steiner, et al. · The Journal of Immunology · 329
PDF
Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer.
1991 · T Blankenstein, Z H Qin, et al. · The Journal of Experimental Medicine · 277
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
2017 · Thomas Kammertoens, Christian Friese, et al. · Nature · 269
Interleukin 7 induces CD4+ T cell-dependent tumor rejection.
1991 · H Hock, M Dorsch, et al. · The Journal of Experimental Medicine · 247
PDF
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
2003 · Zhihai Qin, Johannes Schwartzkopff, et al. · PubMed · 234
PDF
Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes
2003 · Boris Engels, Hakan Cam, et al. · Human Gene Therapy · 202
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
2008 · Anna Kruschinski, Andreas Moosmann, et al. · Proceedings of the National Academy of Sciences · 197
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
2001 · B Seliger, U Wollscheid, et al. · PubMed · 196
High-throughput identification of antigen-specific TCRs by TCR gene capture
2013 · Carsten Linnemann, Bianca Heemskerk, et al. · Nature Medicine · 177
The role of tumor stroma in the interaction between tumor and immune system
2005 · Thomas Blankenstein · Current Opinion in Immunology · 176
Attenuation of collagen‐induced arthritis in mice by treatment with vector cells engineered to secrete interleukin‐13
1996 · Natacha Bessis, Marie‐Christophe Boissier, et al. · European Journal of Immunology · 171
T Helper Cell Type 1–associated and Cytotoxic T Lymphocyte–mediated Tumor Immunity Is Impaired in Interleukin 4–deficient Mice
1999 · Thomas Schüler, Zhihai Qin, et al. · The Journal of Experimental Medicine · 167
Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay
2001 · Christian Becker, Heike Pohla, et al. · Nature Medicine · 152
Tumor Rejection by Disturbing Tumor Stroma Cell Interactions
2001 · Sabrina Ibe, Zhihai Qin, et al. · The Journal of Experimental Medicine · 146
PDF
Expression of interleukin 10 in human melanoma
1994 · S Krüger-Krasagakes, K Krasagakis, et al. · British Journal of Cancer · 140
PDF
Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.
1993 · G Richter, S Krüger-Krasagakes, et al. · PubMed · 136
Analysis of cytokine mRNA levels in interleukin‐4‐transgenic mice by quantitative polymerase chain reaction
1992 · Cornelia Platzer, Günther Richter, et al. · European Journal of Immunology · 135
Transgenic mice with a diverse human T cell antigen receptor repertoire
2010 · Liang-Ping Li, J Christoph Lampert, et al. · Nature Medicine · 123
Works count: 411
Citation count: 13,860
H-index: 58
I10-index: 170
Year
Topic
Type